Coronavirus update: COVID-19 vaccine pre-clinical developments
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
Researchers have been able to manipulate the lifespans of C. elegans by altering the VRK-1 protein, offering a potential target hope for anti-ageing drugs.
A team has discovered channels that enable the transport of lipids between the malaria parasite and red blood cells during infection.
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
Researchers have revealed that the microRNA miR-218-5p promoted hair growth in mice, so is a promising drug target for hair loss.
Dr Santosh Mishra and Srisruti Bontala explain how they discovered a new cutaneous-nerve pathway for allergic itch in atopic dermatitis.